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A number of available treatments provide relief of menopausal symptoms and prevention of postmenopausal
osteoporosis. However, as breast safety is a major concern, new options are needed, particularly agents with an improved
mammary safety profile. Results from several large randomized and observational studies have shown an association
between hormone therapy, particularly combined estrogen-progestin therapy, and a small increased risk of breast
cancer and breast pain or tenderness. In addition, progestin-containing hormone therapy has been shown to increase
mammographic breast density, which is an important risk factor for breast cancer. Selective estrogen receptor modulators
(SERMs) provide bone protection, are generally well tolerated, and have demonstrated reductions in breast cancer risk,
but do not relieve menopausal symptoms (that is, vasomotor symptoms). Tissue-selective estrogen complexes (TSECs)
pair a SERM with one or more estrogens and aim to blend the positive effects of the components to provide relief of
menopausal symptoms and prevention of postmenopausal osteoporosis without stimulating the breast or endometrium.
One TSEC combination pairing conjugated estrogens (CEs) with the SERM bazedoxifene (BZA) has completed clinical
development and is now available as an alternative option for menopausal therapy. Preclinical evidence suggests that
CE/BZA induces inhibitory effects on breast tissue, and phase 3 clinical studies suggest breast neutrality, with no
increases seen in breast tenderness, breast density, or cancer. In non-hysterectomized postmenopausal women, CE/BZA
was associated with increased bone mineral density and relief of menopausal symptoms, along with endometrial safety.
Taken together, these results support the potential of CE/BZA for the relief of menopausal symptoms and prevention of
postmenopausal osteoporosis combined with breast and endometrial safety.Introduction
Vasomotor symptoms (VMSs) occur in up to 88% of
women during the early years of menopause [1], and
vulvar-vaginal atrophy (VVA) symptoms (for example,
vaginal dryness, irritation, soreness, and dyspareunia) are
reported by up to 50% of postmenopausal women [2].
Women also lose bone mineral density (BMD) after
menopause, leading to increased risk of osteoporosis and
fractures [3,4].
Hormone therapy (HT) comprises estrogen therapy
(ET) for hysterectomized women and estrogen-progestin
therapy (EPT) for women with a uterus. Although ET
and EPT effectively treat VMS and VVA and prevent
postmenopausal osteoporosis [5], some regimens are* Correspondence: sebastian.mirkin@pfizer.com
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Other approved agents for prevention or treatment of
postmenopausal osteoporosis - that is, raloxifene (RLX),
bisphosphonates, calcitonin, parathyroid hormone, and
denosumab - do not relieve menopausal symptoms.
Tissue-selective estrogen complexes (TSECs), which
combine a selective estrogen receptor modulator (SERM)
with one or more estrogens, represent a new therapeutic
approach. This strategy aims to relieve menopausal
symptoms and prevent postmenopausal osteoporosis
without negatively impacting breast and endometrial
safety. The recently approved TSEC pairing conjugated
estrogens (CEs) with bazedoxifene (BZA) was evaluated
in a series of phase 3 clinical trials in postmenopausal
women [9-20]. A key issue is whether TSECs exert estro-
genic or anti-estrogenic effects on the breast. This reviewtd. The licensee has exclusive rights to distribute this article, in any medium, for
ime, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
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TSECs in postmenopausal women.
Breast-related effects of estrogen therapy
In clinical settings, HT has been associated with breast
safety issues, including a potential increase in breast can-
cer [6,8], increased mammographic breast density
[21,22], and breast pain or tenderness [7]. Breast cancer
risk appears to be greater with EPT than ET. The ran-
domized, placebo-controlled Women’s Health Initiative
(WHI) study initially reported a lower risk of invasive
breast cancer after a mean of 6.8 years of ET (specifically
CE) use (hazard ratio (HR) 0.77, 95% CI 0.57 to 1.06;
P = 0.06), with separation of the Kaplan-Meier curves
beginning at 2 years [23]. Despite early termination of
the trial and discontinuation of ET by more than 90%
of participants, reduction in breast cancer risk among
those originally randomly assigned to ET persisted and
became statistically significant during continued follow-
up (HR 0.77, 95% CI 0.62 to 0.95; P = 0.02 at a median
of 10.7 years of follow-up), and mortality among those
with breast cancer was also reduced in the ET group
(HR 0.62, 95% CI 0.39 to 0.97; P = 0.04) [24]. In contrast,
the parallel, randomized, placebo-controlled WHI study of
EPT found it to be associated with an increased risk of in-
vasive breast cancer (HR 1.24, 95% CI 1.01 to 1.54; P =
0.003) at study termination (mean of 5.6 years) [8], which
persisted in the postintervention period (HR 1.25, 95%
CI 1.07 to 1.46; P = 0.004 at a mean of 11.0 years of
follow-up) [25]. Furthermore, the WHI study found an
increased risk of breast-cancer related mortality in the
EPT group at long-term follow-up (HR 1.96, 95% CI
1.00 to 4.04; P = 0.049) [25].
The exact mechanism for an association between estro-
gens and breast cancer risk is not fully understood. One
hypothesis argues that binding of estrogens to estrogen
receptors (ERs) stimulates cellular proliferation, which
increases the likelihood that DNA damage will be propa-
gated during cell division, ultimately leading to breast
carcinogenesis [26]. Another hypothesis is that estrogens
are not oncogenic but promote existing occult tumors
[27]. A third suggests that estrogen metabolites such as
the catechol estrogens interact with DNA directly and
have a carcinogenic effect in the breast [28].
Different types of estrogens may exhibit different es-
trogenic effects in breast tissue. For example, in a study
comparing CE and estradiol on the growth and prolife-
ration of MCF-7 breast cancer cells in vitro, estradiol
was approximately 10 times more potent than CE for
stimulating MCF-7 breast cancer overall cell growth and
cellular proliferation [29]. In addition, estradiol inhibited
apoptosis at a lower concentration than CE and, in gene ex-
pression studies, stimulated the expression of progesterone
receptor (PR) and amphiregulin to a greater extent thanCE [29]. In a separate study evaluating estradiol and CE
on the growth of MCF-7 xenografts in a mouse model,
estradiol - but not CE - stimulated tumor growth [30].
Estradiol also induced higher expression of a number of
known ER target genes than did CE, which exhibited
only weak estrogenic activity [30].
Despite progesterone’s anti-proliferative effects on the
endometrium, it has been shown to have proliferative
effects in the breast, independent of estrogen [31]. Pre-
clinical data suggest a number of mechanisms by which
progestins may increase breast cancer risk. One hypo-
thesis is that progestogens activate the stem cell pool and
accelerate tumor formation in the breast or that they
convert some PR+ cells into basal ER−/PR− stem cell-like
cells [32]. The estrogen component of EPT may restore
PR expression (which declines during postmenopause),
allowing stimulation and amplification by the progestin
component of these previously dormant stem cells [32].
In addition, progestins have been shown to stimulate
production of vascular endothelial growth factor and
therefore may promote tumor angiogenesis [33]. Recent
studies have implicated progesterone in breast cancer cell
proliferation through intracellular signaling via the PR
and its various downstream targets and effectors [34,35].
There is also evidence that progestin-activated PR signal-
ing leads to downregulation of the microRNA miR-16, a
potent suppressor of breast cancer cell growth and pro-
liferation [36]. Finally, there is evidence that progestins
increase angiogenesis and decrease apoptosis via diffe-
rential regulation of fibroblast growth factors, indepen-
dent of PR signaling [37].
Increased mammographic breast density is a signifi-
cant risk factor for breast cancer development [38,39],
and high mammographic breast density may decrease
sensitivity for detecting breast abnormalities [40]. New-
onset breast tenderness occurs significantly more fre-
quently in women receiving combined EPT compared
with placebo or CE alone [41] and is associated with in-
creased mammographic breast density [21] and subse-
quent breast cancer risk [41].
Breast-related effects of selective estrogen
receptor modulators
SERMs are structurally diverse compounds that differ
chemically from each other as well as from estrogens
(Figure 1). Like estrogens, SERMs bind to the ER; how-
ever, whereas estrogens are ER agonists, SERMs exhibit
selective agonist and antagonist effects depending on the
target tissue [42]. After an individual SERM binds to the
ER, the SERM-ER complex adopts a unique confor-
mation (Figure 2) that may result in a distinctive pattern
of cofactor recruitment [43]. Each SERM’s activity is de-
rived from its unique ability to direct the structure of
the receptor’s ligand-binding domain and consequently
Figure 1 Structural diversity of estrogens and selective estrogen receptor modulators (SERMs). A chemically diverse group of SERMs and
estrogens all function by binding to estrogen receptors.
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ting in cell- and tissue-specific alterations in gene expres-
sion [43]. Tamoxifen and RLX were initially classified as
anti-estrogens that inhibited estrogen’s stimulatory ac-
tions in breast cancer cells [44]. However, early studies
revealed that these agents could exhibit agonist or antag-
onist activities in different tissues, resulting in their re-
classification as SERMs [44-46]. For example, although
tamoxifen showed anti-estrogenic activity in theFigure 2 Molecular activity of selective estrogen receptor modulators
receptor, the receptor adopts a unique conformation that allows dimerizat
target genes. The unique conformational change induced by binding of th
Reprinted with permission from Elsevier [43].treatment and prevention of breast cancer, it also dem-
onstrated estrogen agonist activity with its bone-
protective and endometrial-stimulatory effects [47,48].
The mechanistic insights gained from studies of tamoxi-
fen and RLX prompted the development of second- and
third-generation SERMs, such as lasofoxifene (LAS),
BZA, arzoxifene, and ospemifene [49]. Like tamoxifen,
arzoxifene has been associated with positive bone effects
and prevention of ER+ breast cancer but also stimulation(SERMs) at estrogen receptors. When a SERM binds to the estrogen
ion and interaction with estrogen response elements (EREs) of the
e SERM may result in a distinct pattern of cofactor recruitment.
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cated only for the treatment of moderate to severe dys-
pareunia, a symptom of VVA, due to menopause [53].
The impact of the other SERMs on the breast is dis-
cussed below.
Tamoxifen
Tamoxifen, which has been in clinical use for approxi-
mately 40 years, is approved by the US Food and Drug
Administration for treatment of metastatic breast cancer,
adjuvant treatment of node-positive and axillary node-
negative breast cancer, ductal carcinoma in situ, and
breast cancer risk reduction in women at high risk [54].
Preclinical results demonstrated inhibitory effects of
tamoxifen on growth of ER+ tumors [55,56], and an ex-
tensive body of clinical evidence supports the efficacy of
tamoxifen in treatment and risk reduction of breast can-
cer [57]. Tamoxifen is associated with a reduction in
breast density [58], which has been positively associated
with reduced breast cancer risk [59]. For example,
Cuzick and colleagues [59] showed that tamoxifen-
treated patients with a reduction in breast density of at
least 10% experienced a 63% reduction in breast cancer
risk (odds ratio 0.37, 95% CI 0.20 to 0.69) but that
tamoxifen-treated patients with a reduction in breast
density of less than 10% showed no risk reduction. Al-
though many of its effects are beneficial, tamoxifen has
been associated with an increased risk of thrombo-
embolic events and endometrial cancer, which has led to
a search for alternative agents for treatment and preven-
tion of breast cancer [57].
Raloxifene
RLX is approved for prevention and treatment of post-
menopausal osteoporosis and for reduction in risk of in-
vasive breast cancer in postmenopausal women with
osteoporosis or at high risk for invasive breast cancer
[60]. In preclinical studies, RLX did not promote the
proliferation of MCF-7 breast cells [61,62]. A study by
Lewis-Wambi and colleagues [63] compared the effects
of BZA, 4-hydroxytamoxifen, endoxifen, RLX, and ful-
vestrant (a pure anti-estrogen) on the growth of
hormone-dependent and hormone-independent MCF-7
breast cancer cell lines. RLX inhibited estrogen-
stimulated breast cancer cell proliferation but did not in-
hibit proliferation of hormone-independent breast can-
cer cells. RLX is generally an ER antagonist in breast
tissue; however, RLX may stimulate expression of certain
ER genes. For example, in ovariectomized (OVX) mice,
RLX upregulated expression of the mammary gland ex-
pression marker indoleamine-pyrrole 2,3 dioxygenase
compared with vehicle control, which is indicative of
ER agonist activity [64]. Nonetheless, clinical studies
consistently show a reduced incidence of breast cancer inwomen receiving RLX [65-68]. For example, in the ran-
domized, double-blind, Multiple Outcomes of Raloxifene
Evaluation (MORE) trial of postmenopausal women with
osteoporosis (n = 7,705), RLX decreased the risk of inva-
sive breast cancer by 72% over 4 years compared with
placebo (PBO) (relative risk (RR) 0.28, 95% CI 0.17 to
0.46) [65]. In the 4-year Continuing Outcomes Relevant
to Evista (CORE) extension of the MORE study (n =
4,011), reduced risk of invasive breast cancer by RLX was
maintained versus PBO (HR 0.41, 95% CI 0.24 to 0.71)
[66]. At long-term follow-up (n = 19,490) of the rando-
mized, double-blind Study of Tamoxifen and Raloxifene
trial, RLX was less effective than tamoxifen for preven-
tion of invasive breast cancer (RR 1.24, 95% CI 1.05 to
1.47) and ductal carcinoma in situ (RR 1.22, 95% CI 0.88
to 1.69) [68]. The incidence of breast pain was similar
with RLX and PBO in the MORE [65] and CORE [66]
studies, but in the Euralox-1 study of healthy postmeno-
pausal women (n = 1,008), the incidence of breast pain
was significantly lower with RLX than with HT (1.8%
versus 26.5%, respectively; P <0.001) [69]. A recent re-
view concluded that RLX did not increase or decrease
mammographic breast density [70]; however, many of the
studies assessing the effect of RLX on breast density have
been relatively small (fewer than 200 patients), and
methods of measuring breast density have not been con-
sistent [71-73].Lasofoxifene
LAS was developed for treatment of vaginal atrophy and
prevention and treatment of postmenopausal osteo-
porosis [74]. LAS exhibited anti-proliferative effects in
estrogen-sensitive MCF-7 breast cancer cells [62,75] and
did not change the histology of mammary tissue in OVX
cynomolgus macaques [76]. The 5-year Postmenopausal
Evaluation and Risk-reduction with Lasofoxifene study
(n = 8,556) demonstrated an 81% reduction in risk of
total ER+ breast cancer and an 83% reduction in risk of
invasive ER+ breast cancer with LAS 0.5 mg/day versus
PBO (P <0.001) [77]. Pooled results from two identical
phase 3 studies of varying doses of LAS in postmeno-
pausal women (n = 1,907) showed no increase in breast
density or breast pain with LAS versus PBO [78]. LAS
received European Union (EU) marketing authorization
from the European Commission in 2009. A series of in-
dustry acquisitions, asset shifts, and licensing of product
rights has since ensued, delaying its launch. Since LAS
did not become commercially available within 3 years,
its EU approval has lapsed but may be reapplied for
eventually or it may become available as an unlicensed
medicinal product available by physician request for pa-
tients who are not candidates for approved therapies
[79,80].
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BZA is a newer-generation SERM that has demonstrated
efficacy for the prevention and treatment of postmeno-
pausal osteoporosis [81,82]. Its development was
prompted by the need for improved SERMs that could
protect the skeleton, improve lipid profile, reduce hot
flush frequency and severity, reduce vaginal dryness and
atrophy, and maintain bladder function without stimu-
lating the endometrium or breast [83]. During precli-
nical development, BZA was shown to be a functionally
active ER ligand with beneficial effects on bone and total
cholesterol, antagonist activity in the breast, and neutral
effects on the endometrium; however, it did not inhibit
vasomotor response when given at a bone-protective
dose [83]. Although a discussion of the full range of ef-
fects of BZA and other SERMs is beyond the scope of
this article, a review of this topic was recently published
[84], as was a review of the differential effects of meno-
pausal therapies on the endometrium [85].
Further preclinical investigations confirmed that BZA
acts as an estrogen antagonist in the breast. In MCF-7 pro-
liferation assays, BZA did not stimulate cell proliferation
and potently inhibited estradiol-stimulated proliferation
[61]. In the previously described study by Lewis-Wambi
and colleagues [63], all of the compounds studied inhibited
estradiol-stimulated breast cancer cell proliferation, but
only BZA and fulvestrant significantly inhibited the growth
of hormone-independent MCF-7:5C cells [63]. Growth
inhibition of MCF-7:5C with BZA was associated with
cell cycle arrest and downregulation of cyclin D1 and ERα
[63]. In a separate study evaluating the effects of BZA on
the growth of breast cancer xenografts in mouse models,
BZA inhibited the growth of tamoxifen-sensitive and
tamoxifen-resistant tumor xenografts [86]. Unlike other
SERMs, BZA downregulates ER expression and therefore
shares some properties of selective estrogen receptor de-
graders, such as the pure anti-estrogen fulvestrant [86].
The extent to which this contributes to growth inhibition
of tumor xenografts is unclear, but BZA exhibits anta-
gonist activity in breast cancer cells in vitro independent
of ER degradation [86].
BZA’s lack of ER-stimulatory activity in the breast is
reinforced by data from phase 3, randomized, double-
blind studies in postmenopausal women [87-89]; how-
ever, these studies were not sufficiently powered to de-
tect breast cancer prevention. In a 2-year trial of varying
doses of BZA, RLX 60 mg, and PBO in healthy post-
menopausal women at risk for osteoporosis (n = 1,583),
rates of breast carcinoma (0% to 0.6%) and breast pain
(2.6% to 3.7%) were low and similar among treatment
groups [87]. A phase 3, randomized, double-blind, 3-
year trial of BZA (20 or 40 mg), RLX 60 mg, or PBO in
women with osteoporosis (n = 7,492) showed no signifi-
cant difference in the incidence of breast carcinoma andbreast cysts with BZA compared with PBO or RLX;
however, there was a significantly lower incidence of
fibrocystic breast disease with BZA 20 or 40 mg (0.3%
and 0.2%, respectively) versus RLX (0.8%; both P ≤0.05)
[88,89]. Breast pain incidence was similar among groups,
with rates ranging from 2.4% to 3.0% [88,89]. In a retro-
spective ancillary analysis of a subset of women (n = 444)
from this study, mean percentage changes in breast
density from baseline were low and similar among
groups [90]. Consistent with the 3-year results, BZA
showed a neutral effect on the breast at 5 years [91] and
7 years [92] of therapy.
Breast-related effects of the tissue-selective
estrogen complex
As described above, SERMs are generally well tolerated
and have not been shown to stimulate the breast. How-
ever, no SERM alone achieves an optimal balance of
providing ER agonist activity to relieve menopausal
symptoms and prevent bone loss while exerting antag-
onist effects on the breast. By pairing a SERM with
one or more estrogens, the TSEC blends estrogenic
properties with the tissue-selective activity of a SERM
[93] with the goals of relieving menopausal symptoms
and preventing bone loss while minimizing estrogenic
effects on the endometrium and breast [93]. In com-
parison with EPT, a more favorable breast safety profile
was expected for TSECs given the lack of a progestogen
component, which (as noted above) has been associated
with an increased risk of breast cancer compared with
estrogens alone [94].
Molecular activity of the TSEC components at the re-
ceptor level may help explain differences in their activity
compared with that of individual estrogens and SERMs.
With a TSEC, competition of the SERM and estrogen
components for binding to ERs is expected to result in
unique combinations of ERs with conformations reflect-
ing both SERM and estrogens. Furthermore, since
SERMs and estrogens both bind to ERs, it is possible
that their combination facilitates formation of novel re-
ceptor dimers that bind to both SERMs and estrogens
rather than one or the other. Results of a recent study
support the cooperative interaction of SERMs and estro-
gens through a heterodimeric complex [95]. Using an
in vitro reporter gene assay, the cooperative control of
gene expression by ER agonists (for example, CE and
17β-estradiol) and antagonists (for example, tamoxifen,
RLX, BZA, and fulvestrant) was shown to be mediated
through an ER heteroligand dimer complex, in which
the ER agonist binds to one dimer subunit and the an-
tagonist binds to the other [95]. The actions of TSEC
within a given cell type may also reflect the net effect of
TSECs on both receptor and cell environment integrated
at the level of gene expression (for example, estrogens
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could promote SERM activity and vice versa) [96].
Preclinical comparisons of different tissue-selective estro-
gen complexes
The breast-related effects of different TSECs, combining
RLX, LAS, or BZA with one or more estrogens, have
been evaluated in preclinical studies (Table 1)
[30,62,64,97-99].
In vitro studies
Berrodin and colleagues [97] evaluated the effects of
BZA, RLX, and LAS on CE-mediated recruitment of 43
cofactor peptides to the ERα-ligand-binding domain by a
multiplex biochemical assay. LAS and RLX in combi-
nation with CE completely inhibited the CE-mediated
recruitment of all peptides [97]. In contrast, BZA in
combination with CE inhibited the CE-mediated recruit-
ment of some, but not all, of the evaluated cofactor pep-
tides, indicating the potential for tissue selectivity with
CE/BZA and suggesting that CE/BZA induces different
conformations of ERα than either CE/RLX or CE/LAS
[97]. The investigators also studied gene expression pro-
files in MCF-7 breast cancer cells and found that CE/BZA
exhibited an expression profile for a subset of genes in the
global gene expression profile that maintained some of theTable 1 Preclinical results
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BZA alone had neutral ef
BZA, bazedoxifene; CE, conjugated estrogens; ER, estrogen receptor; LAS, lasofoxifecharacteristics of CE alone, whereas CE/RLX and CE/LAS
completely antagonized expression of this subset of CE-
regulated genes [97]. The CE-regulated genes antagonized
by all three of these SERMs were involved in cell cycle
regulation and cell-to-cell signaling [62,97]. Results from
microarray studies comparing gene expression profiles of
BZA, RLX, and LAS alone and in combination with CE in
MCF-7 human breast cancer cells also supported a broad
range of differences in gene expression patterns across the
different SERM and TSEC combinations [62,96]. In an
MCF-7 cell proliferation study, RLX, LAS, and BZA all
significantly antagonized CE-stimulated proliferation of
breast cancer cells; BZA exhibited similar or better efficacy
at inhibiting MCF-7 cell growth than the other SERMs
evaluated [62].
In vivo studies
Results of in vivo preclinical studies provide further evi-
dence of differences in the activity of TSECs combining
different SERMs with CE (Table 1) [64,98]. In the mam-
mary gland of OVX mice, treatment with BZA and RLX
(but not LAS), when given in combination with estradiol,
reduced estradiol-induced mammary gland end bud pro-
liferation [64]. In a separate study of the effects of BZA,
RLX, and LAS alone and in combination with CE on
mammary gland morphology in OVX sexually immatureinhibited CE-mediated recruitment of all cofactor peptides to the
ain, whereas CE/BZA inhibited the CE-mediated recruitment of some,
profile was significantly different from CE/LAS or CE/RLX.
BZA antagonized genes involved in cell cycle regulation and growth
LX and CE/LAS also antagonized expression of a set of CE-regulated
/BZA.
BZA all antagonized CE-stimulated proliferation, with antagonism levels
A > RLX > LAS.
profile was significantly different from CE/LAS or CE/RLX.
duced estradiol-induced mammary gland end bud proliferation.
ker studies in the mammary gland showed that BZA, RLX, and LAS all
ts but have different degrees of agonist activity.
CE-induced increases in ductal tree branch points; RLX and LAS only
uced effects.
nic effects of CE and estradiol (including ductal length, terminal end
ration, apoptosis, and gene expression changes).
duced tumor growth and weight.
stimulatory effects on total breast epithelial density, Ki67 staining, markers
ar size.
fects on all outcomes.
ne; RLX, raloxifene.
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CE-induced effects [98]. CE activity in the breast and
uterus was antagonized by BZA to a greater extent than
by RLX or LAS [98].
Overall, preclinical data support the concept that
TSECs exhibit distinct pharmacologic profiles. In many
tissues, BZA and CE exhibit opposite effects on shared
ER target genes (for example, growth-related genes may
be upregulated by estrogens and downregulated by
BZA), whereas some genes (for example, FOS, CYR61,
and ZNF10) are regulated in the same direction by both
BZA and CE [62]. These observations suggest that BZA
selectively antagonizes certain aspects of CE action but
may work in concert with CE at a subset of genes [62].
In contrast, results of gene expression profiling studies
indicate that RLX or LAS in combination with CE an-
tagonizes the expression of a greater number of CE-
regulated genes, which theoretically could limit CE’s
beneficial effects (for example, on vasomotor symptoms)
[97]. Further preclinical and clinical data for CE/BZA,




The breast safety profile of CE/BZA has been evaluated
in murine and primate models [30,99]. In a study com-
paring estradiol, CE, and BZA, BZA blocked the estro-
genic effects of CE or estradiol on ductal length,
terminal end bud development, proliferation, apoptosis,
and gene expression changes on mammary gland tissue
and inhibited the growth and weight increase of tumors
in human MCF-7 xenografts in OVX mice [30]. In the
mammary gland of OVX cynomolgus macaques, CE
stimulation of total breast epithelial density, Ki67 stai-
ning, markers of ERα activity, and lobular size were an-
tagonized by treatment with CE/BZA [99]. On the basis
of gene markers of cell proliferation or cell cycle pro-
gression, both BZA and CE/BZA lacked estrogen activity
in the breast. The investigators suggested that ERα pro-
tein degradation may play a role in the inhibitory breast
effects of BZA [99]. Along with the previously described
results of comparative studies of CE/BZA and other
TSEC combinations, these results suggest that CE/BZA
can antagonize estrogenic activity in normal and cancer-
ous breast tissue.
Clinical studies
The efficacy and safety of CE/BZA were evaluated in the
Selective estrogens, Menopause, And Response to Therapy
(SMART) trials, five randomized, double-blind, placebo-
and active-controlled, phase 3 trials that enrolled postmen-
opausal women with a uterus (Table 2) [9-19,100-102].
Overall, the SMART trials demonstrated increased BMDand relief of VMS and VVA with CE/BZA treatment
(Table 2) while ensuring endometrial safety and breast pro-
tection (Table 3). On the basis of these studies, CE
0.45 mg/BZA 20 mg once daily was approved in 2013 by
the US Food and Drug Administration for treatment of
moderate to severe VMSs associated with menopause and
for prevention of postmenopausal osteoporosis in women
with a uterus [103].
Breast safety outcomes from clinical studies
The incidence of breast-related adverse events was low
and similar for CE 0.45 mg/BZA 20 mg compared with
PBO in a pooled analysis of the SMART-1 to −3 trials
[104]. In SMART-1 (n = 3,397), the incidences of abnor-
mal mammograms at 2 years were similar for CE
0.45 mg/BZA 20 mg (4.4%) and PBO (2.6%) [100]. Simi-
larly, in SMART-5 (a placebo-controlled comparison of
CE/BZA and HT, n = 1,843), incidences of abnormal
mammograms at 1 year were similar for CE 0.45 mg/BZA
20 mg (0.9%) and PBO (0.2%) [18].
Breast cancer rates were low across the SMART stu-
dies [18,104], although it is important to note that these
studies were not powered to demonstrate breast cancer
prevention. In a pooled analysis of the SMART-1 to −3
studies, the rate of breast cancer in the CE 0.45 mg/BZA
20 mg group (0.25%) was similar to that in the placebo
group (0.17%) [104].
CE/BZA does not appear to affect breast density. In an
ancillary retrospective study of SMART-1 (n = 507),
mean mammographic breast density changes at 2 years
with CE 0.45 mg/BZA 20 mg (−0.39%) were similar to
those with PBO (−0.42%) and RLX 60 mg (−0.23%)
[100]. Similarly, in the breast density substudy of
SMART-5, CE 0.45 mg/BZA 20 mg was not associated
with increased breast density and demonstrated non-
inferiority compared with PBO at 12 months [18]. In
contrast, CE 0.45 mg/medroxyprogesterone acetate
(MPA) 1.5 mg was associated with a significant increase
in breast density at 12 months versus PBO [18].
Breast pain and tenderness outcomes from clinical studies
There was no significant difference between the CE
0.45 mg/BZA 20 mg and PBO groups in the percentage
of women reporting breast pain or tenderness in any
SMART trial [10,13,15,17,18]. In SMART-1 (n = 3,397),
the incidence of breast pain among the CE/BZA, RLX,
and PBO group was not significantly different [10]. In
the SMART-2 (n = 332), SMART-3 (n = 664), and
SMART-4 (n = 1,061) trials, there were no significant
differences in the number of women reporting at least
1 day of breast pain between the CE/BZA and PBO
groups [13,15,17]. In SMART-5 (n = 1,843), the incidence
of breast tenderness with CE/BZA was similar to PBO
and significantly lower than with CE/MPA (P <0.001)
Table 2 The SMART clinical trial program


















































OSS I: >5 YSM with a
baseline BMD T-score
between −1 and −2.5








at 2 years: 4.4% with
CE 0.45 mg/BZA 20 mg,
4.2% with CE 0.625 mg/BZA
20 mg, 3.4% with RLX,
and 2.6% with PBO [100]
OSS II: 1–5 YSM with
≥1 risk factor for
osteoporosis [12]
CE 0.625 and 0.45 mg/BZA
20 and 40 mg associated
with rates of cumulative
amenorrhea similar to PBO
(>83% (cycles 1–13)
and >93% (cycles 10–13));
bleeding and spotting








PBO CE 0.45 and 0.625 mg/BZA
20 mg significantly reduced
number (P <0.05 for both)
and severity (P <0.001 for
both) of hot flushes vs. PBO
at week 12 [10]
CE 0.625 and 0.45 mg/BZA
20 mg significantly reduced







CE 0.45 and 0.625 mg/BZA
20 mg significantly improved
LDL and HDL cholesterol
vs. PBO (P <0.01 for all)
at month 24 [10]
OSSs
In both OSSs, CE/BZA was
associated with significant
BMD increases at lumbar
spine (P <0.001) and total
hip (P <0.01), with significant
decreases in bone turnover
markers [12]
Smith et al. Breast Cancer Research Page 8 of 152014, 16:212
http://breast-cancer-research.com/content/16/3/212









































Other outcomesWith a uterus






































































≤5% or less superficial
cells on vaginal
cytological smear





















CE 0.45 and 0.625 mg/BZA
20 mg significantly improved
sexual function measured by
ASEX (P <0.05) vs. PBO [16]
CE 0.45 and 0.625 mg/BZA





(P <0.01) vs. PBO [16]











There were 3 cases of
endometrial hyperplasia
in the CE 0.625 mg/BZA
20 mg group and none
in the other groups
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with CE 0.45 and
0.625 mg/BZA 20 mg
was low (≤0.3%)
































in lumbar spine BMD
vs. PBO at 1 year
(P <0.001) [101]
Other outcomes
CE 0.45 and 0.625 mg/BZA
20 mg were non-inferior to








in sleep parameters and
HRQOL at 1 year [19]
17β-E2, 17β-estradiol; ASEX, Arizona Sexual Experiences Scale; BMD, bone mineral density; BMI, body mass index; BZA, bazedoxifene; CE, conjugated estrogens;
FSH, follicle-stimulating hormone; HDL, high-density lipoprotein; HR-QOL, health-related quality of life; LDL, low-density lipoprotein; MENQOL, Menopause-specific
Quality of Life; MPA, medroxyprogesterone acetate; OSS, Osteoporosis Substudy; PBO, placebo; RLX, raloxifene; SMART, Selective estrogens, Menopause, And
Response to Therapy; VVA, vulvar-vaginal atrophy; YSM, years since menopause.
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Table 3 Breast safety results from the SMART clinical trial program
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CE 0.45 mg/MPA 1.5 mg,
breast pain incidence
was significantly lower
with CE 0.45 mg/BZA
20 mg at weeks 5–8
and 9–12 (P <0.05) and
for CE 0.625 mg/BZA






n (%) at 2 years:
CE 0.45 mg/BZA
20 mg, 13 (4.4%)









RLX 60 mg, 9 (3.4%) BZA 20 mg, 1 (0.4%)
PBO, 7 (2.6%) [100] CE 0.45 mg/MPA
1.5 mg,
3 (1.4%)







ND ND ND No significant
differences from PBO
with CE 0.45
mg/BZA 20 mg or






Mean (SD) percentage change from
baseline in percentage breast density










CE 0.625 mg/BZA 20 mg, −0.05%
(1.68%)
RLX 60 mg, −0.23% (1.76%)
PBO, −0.42% (1.72%) [100] CE 0.625 mg/BZA
20 mg, −0.44% (0.22%)
BZA 20 mg, −0.24%
(0.30%)
CE 0.45 mg/MPA
1.5 mg, 1.60% (0.35%)
PBO, −0.32% (0.23%)
[18]
BZA, bazedoxifene; CE, conjugated estrogens; MPA, medroxyprogesterone acetate; ND, not determined; PBO, placebo; RLX, raloxifene; SD, standard deviation;
SMART, Selective estrogens, Menopause, And Response to Therapy.
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related safety and tolerability profile of CE/BZA in
postmenopausal women with a uterus.
Conclusions
A number of available treatments provide effective relief
of VMS and VVA along with prevention of postmeno-
pausal osteoporosis, but new options with improved
breast-related safety and tolerability are needed. Results
from large randomized and observational studies have
shown an association between HT, particularly EPT, and
increased risk of breast cancer [6-8]. HT use by post-
menopausal women has been associated with increased
mammographic breast density [21,22], which is a risk
factor for breast cancer [38,39]. Breast pain and tender-
ness are also a concern with HT.
SERMs are generally well tolerated and have demon-
strated positive effects on the breast but do not relieve
menopausal symptoms. A TSEC aims to take advantage
of the positive effects of both the SERM and the estrogen
components to treat menopausal symptoms and prevent
postmenopausal osteoporosis without stimulating the
breast or endometrium. Strong preclinical evidence sup-
ports the breast safety of CE/BZA. Clinically, CE/BZA
has shown no or minimal increased risk of breast effects,
and the results of phase 3 clinical trials have demon-
strated a favorable breast-related safety and tolerability
profile in non-hysterectomized postmenopausal women.
Additional studies are necessary to elucidate the effects,
if any, of HT, SERMs, and TSECs on occult pre-existing
breast tumors.
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